Linked Life Data

11264732

Source:http://linkedlifedata.com/resource/pubmed/id/11264732

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-3-26
pubmed:abstractText
Recent results of clinical trials suggest that combination of interferon and ribavirin exhibits an enhanced antiviral effect in the treatment of chronic hepatitis C. To investigate the effect of ribavirin on hepatitis C virus (HCV) infection, we analysed the evolution of the genetic heterogeneity of HCV in relation to the anti-HCV humoral response in patients treated by ribavirin alone. The study population included 35 patients with liver biopsy proven chronic hepatitis C infected with HCV genotype 1. Among them, 26 were treated with ribavirin for at least 12 months and nine untreated patients served as a control group. Serum samples were analysed before and at 6 and 12 months of therapy. Three regions of the HCV genome, i.e. HVR1, a domain of NS5A including part of the interferon sensitivity determining region (ISDR), and a segment of NS5B, were amplified by RT-PCR using specific primers. The PCR products were then studied using single-strand conformation polymorphism (SSCP) analysis followed by either direct sequencing, or cloning and sequencing. In parallel, the humoral anti-E1 response was studied using an ELISA (Innotest HCV E1Ab, Innogenetics). The results of HCV genome analysis showed no significant effect on the amino acid sequence evolution of the HVR1, NS5A and NS5B regions of HCV. Analysis of a phylogenetic tree from the major quasispecies variants showed the absence of correlation with ribavirin response, and the absence of selection of viral strains during ribavirin treatment. A trend towards a decrease in the anti-E1 Ab response was also observed. Altogether these results suggest that ribavirin may not exhibit a direct antiviral effect, but may trigger a favourable response to interferon by modulating the immune response against HCV.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1352-0504
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
120-31
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11264732-Amino Acid Sequence, pubmed-meshheading:11264732-Antiviral Agents, pubmed-meshheading:11264732-Evolution, Molecular, pubmed-meshheading:11264732-Female, pubmed-meshheading:11264732-Genome, Viral, pubmed-meshheading:11264732-Genotype, pubmed-meshheading:11264732-Hepacivirus, pubmed-meshheading:11264732-Hepatitis C, pubmed-meshheading:11264732-Hepatitis C, Chronic, pubmed-meshheading:11264732-Hepatitis C Antibodies, pubmed-meshheading:11264732-Humans, pubmed-meshheading:11264732-Interferons, pubmed-meshheading:11264732-Male, pubmed-meshheading:11264732-Middle Aged, pubmed-meshheading:11264732-Molecular Sequence Data, pubmed-meshheading:11264732-Ribavirin, pubmed-meshheading:11264732-Sequence Alignment, pubmed-meshheading:11264732-Viral Nonstructural Proteins, pubmed-meshheading:11264732-Viral Proteins, pubmed-meshheading:11264732-Viral Structural Proteins
pubmed:year
2001
pubmed:articleTitle
Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
pubmed:affiliation
INSERM Unit 271, 151 cours Albert Thomas, 69003 Lyon, France.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't